Drug Profile
Bimatoprost/brimonidine
Alternative Names: Brimonidine/bimatoprostLatest Information Update: 19 May 2020
Price :
$50
*
At a glance
- Originator Allergan
- Class Amides; Antiglaucomas; Antihypertensives; Lipids; Prostaglandins; Quinoxalines; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor agonists; Prostaglandin F2alpha receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Glaucoma; Ocular hypertension
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 26 Sep 2019 Discontinued - Phase-II for Glaucoma in USA (Ophthalmic)
- 26 Sep 2019 Discontinued - Phase-II for Ocular hypertension in USA (Ophthalmic)